All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The EMA published the first summary for the public of the risk-management plan (RMP) of a newly authorized drug. The summary describes what is known and not known about the safety of Mumbai, India-based Piramal Imaging SA’s Neuraceq (florbetaben) and what measures will be taken to prevent or minimize the risks of the radiopharmaceutical used in brain scans.